Sanofi

@sanofi

An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: bit.ly/sanofi-terms

Paris

sanofi.com

Replies Reposts Media

Sanofi
@sanofi
Jul 30
Our Q2 2026 results are now available. Read the full press release for detailed insights: spkl.io/60197KQtR #SanofiResults $SAN $SNY
6
Sanofi
@sanofi
Jul 24
#NEWS: Update on our phase 3 program in moderate-to-severe #AtopicDermatitis. Learn more ⬇️ spkl.io/60127JNVK
Sanofi
@sanofi
Jun 30
#NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: sanofi.com/en/media-room/…
Sanofi
@sanofi
Jun 23
#NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: sanofi.com/en/media-room/…
1
Sanofi
@sanofi
Jun 23
#NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ sanofi.com/en/media-room/…